2',4'-bridged nucleosides for hcv infection

A compound according to Formula 3001:

• or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein:
• each PD is independently
• each B is independently a nucleobase;
• each W is independently —O—, —NH—, —CHF—, —CF2— or —CH2—;
• each X is independently —C(O)—, —NH—, —CRERE— or —C(═CRR)—;
• each A is independently O or S;
• each of Y and Z is independently —OR1, —SR1, —NR1R2, an N-linked or O-linked amino acid residue, or derivative thereof;
• each RB is independently hydrogen, hydroxyl, fluoro, azido, amino, alkylcarbonylamino, alkoxycarbonylamino, alkylsulfonylamino, or thiol;
• or, in the alternative, Y and RB join to form a six-membered heterocyclic ring wherein Y and RB together represent a single divalent —O—, and Z is —OR1, —SR1, —NR1R2, an N-linked or O-linked amino acid residue, or derivative thereof;
• each RA is independently hydrogen or cyano;
• each RC is independently hydrogen, alkyl, alkoxyl, or halo;
• each RD is independently hydrogen or alkyl;
• each RE is independently hydrogen, fluoro, alkyl, cycloalkyl, aryl, or heteroaryl;
• each R1 is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, arylalkyl, heteroarylalkyl, alkylcarbonylthioalkyl, alkoxylcarbonylalkyl, alkoxylcarbonylthioalkyl or hydroxylalkylcarbonylthioalkyl;
• each R2 is independently hydrogen or alkyl;
• or R1 and R2, together with the atoms to which they are attached, combine to form a 3-10 membered heterocyclic ring;
• and
• each R is independently hydrogen, alkyl, cycloalkyl, aryl, or heteroaryl;
• provided that when:
• RB is hydrogen, hydroxyl, or azide;
• W is —O—;
• X is —CH2—;
• PD is
• A is O;
• Y is —OPh or —OPhCl;
• Z is —NHCH(CH3)C(O)OCH3 or —NHCH(CH3)C(O)OBn;
• and RA, RC and RD are hydrogen, then B is not adenine or thymine.